Establishes 2026 Guidance: Revenue Range of $18 Million to $22 Million with Positive Net Operating Income and Adjusted EBITDA Profitability SCOTTSDALE, Ariz., March 25, 2026 (GLOBE NEWSWIRE) — Caliber (Nasdaq: CWD), a diversified real estate and digital asset management platform, today reported results for the fourth quarter and full year ended December 31, 2025. Caliber enters 2026 with a streamlined platform and a clear path toward revenue growth and profitability, driven by the expected execution of project-level financings and continued capital formation activities. Fourth Quarter 2025 (compared to Fourth Quarter 2024)Platform revenue of $4.0 million, compared to $4.6 millionAsset management revenue of $4.0 million drove the stated resultsPlatform net loss of $7.7 million, or $1.24 per diluted share, compared to Platform...

All dollar amounts are in USD unless otherwise indicated and abbreviation “M” means million. VANCOUVER, British Columbia, March 25, 2026 (GLOBE NEWSWIRE) — Orezone Gold Corporation (TSX: ORE | ASX: ORE | OTCQX: ORZCF) (“Orezone” or “Company”) is pleased to report its operational and financial results for the fourth quarter and year ended December 31, 2025, and its 2026 guidance. The Company will host a conference call and webcast today at 2:00pm PT / 5:00pm ET to discuss the results. Details to join the conference call and webcast are provided at the end of this release. Fourth Quarter 2025 HighlightsGold production of 30,407 oz at an AISC of $1,942 per ounce sold. Revenue of $130.5M from the sale of 31,526 oz at an average realized price of $4,129 per oz. Adjusted EBITDA of $63.0M, Adjusted Earnings attributable to Orezone shareholders...

Conference Call to be Held Thursday, March 26, 2026 at 10:00 a.m. Eastern Time QUINCY, Mass., March 25, 2026 (GLOBE NEWSWIRE) — Stran & Company, Inc. (“Stran” or the “Company”) (NASDAQ: SWAG) (NASDAQ: SWAGW), a leading outsourced marketing solutions provider that leverages its promotional products and loyalty incentive expertise, today announced its financial results for the fiscal year ended December 31, 2025, and provided a business update. Management will host a conference call at 10:00 a.m. Eastern Time on Thursday, March 26, 2026. 2025 Financial HighlightsSales: $116.2 million, an increase of 40.6% year-over-year EBITDA: $0.2 million, compared to $(3.6) million in 2024 and an improvement of $3.8 million Gross Profit: $34.2 million, representing a gross margin of 29.5% Cash, Cash Equivalents, and...

Added top-rated children’s hospitals to QUELIMMUNE™ pediatric Acute Kidney Injury (AKI) customer base Completed enrollment in FDA-mandated QUELIMMUNE SAVE Post-Marketing Registry Exceeded 50% enrollment milestone in pivotal trial of SCD therapy in adult patients with AKI Advanced pipeline indications with initiation of cardio-renal clinical trial Webcast today at 4:30 pm Eastern Time DENVER, March 25, 2026 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today financial results for the three months and year ended December 31, 2025, and provided business updates on key initiatives. “In 2025, we broadened our customer base of top-ranked children’s...

Initiation of Phase 1 proof-of-mechanism study of EQ504 planned for mid-2026, with data expected approximately six months thereafter Cash and cash equivalents, inclusive of the March 2026 financing, expected to fund operations into 2029 LA JOLLA, Calif, March 25, 2026 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for its fourth quarter and fiscal year ended December 31, 2025. “2025 was a transformative year as we sharpened our strategic focus on EQ504 and strengthened our financial position to support its advancement into the clinic,” said Bruce Steel, Chief Executive Officer of Equillium. “Our financing in August 2025 of...

Quarterly Revenue Surges 36% as Gross Margin Expands to 69.8% LOUISVILLE, Ky., March 25, 2026 (GLOBE NEWSWIRE) — LogicMark, Inc. (OTC: LGMK) (the “Company”), a provider of personal safety and emergency response systems (PERS), health communications devices, and technology for the growing care and safety economy, today announced financial and operational results for the fourth quarter and year ended December 31, 2025. Fourth Quarter and Full Year 2025 Financial Highlights  Revenue: Fourth-quarter revenue increased 36% to $3.1 million. Full-year revenue increased 15% to $11.4 million. Revenue has increased year-over-year in six of the last seven quarters. Gross margin: Fourth quarter gross margin increased to 69.8%. Full-year gross margin remained strong at 66.8%. Operating expenses: Fourth quarter operating expenses increased modestly...

FAIRFAX, Va., March 25, 2026 (GLOBE NEWSWIRE) — WidePoint Corporation (NYSE American: WYY), a federally certified provider of Trusted Mobility Management (TM2) solutions, reported results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 and Recent Operational Highlights:34th consecutive quarter of positive Adjusted EBITDA 9th consecutive quarter of positive Free Cash Flow Awarded $1.3 million managed services contract with a leading bottler in the beverage industry Awarded $1.25 million task order under the Navy Spiral 4 Contract for the U.S. Army Secured estimated $40 million to $45 million SaaS contract to deliver FedRAMP-authorized ITMS platform for a major telecommunications carrier Awarded new CWMS 2.0 task order by U.S. Customs & Border Protection valued up to $27.5 millionFourth Quarter...

Fourth Quarter 2025 Comparable Restaurant Sales Increased 6.6% System-WideFirst Quarter 2026 Comparable Restaurant Sales Increased Over 9% To Date BROOMFIELD, Colo., March 25, 2026 (GLOBE NEWSWIRE) — Noodles & Company (Nasdaq: NDLS) today announced financial results for the fourth quarter and fiscal year ended December 30, 2025, and provided a 2026 business outlook. Key highlights for the fourth quarter of 2025 compared to the fourth quarter of 2024 include:Total revenue increased 0.8% to $122.8 million from $121.8 million. Comparable restaurant sales increased 6.6% system-wide, including a 7.3% increase for company-owned restaurants and a 3.8% increase for franchise restaurants. Net loss was $6.8 million, or $1.16 loss per diluted share, compared to net loss of $9.7 million, or $1.70 loss per diluted share. Operating margin...

VANCOUVER, British Columbia, March 25, 2026 (GLOBE NEWSWIRE) — LEEF Brands, Inc. (CSE: LEEF) (OTCQB: LEEEF) (“LEEF” or the “Company”), a rapidly growing cannabis company, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 HighlightsRevenue of $8.3 million, an increase of 38.9% year-over-year Gross profit of $3.8 million, up 188.2% year-over-year Gross margin of 45.5%, an increase of 23.5 percentage points year-over-year Adjusted EBITDA of $1.0 million, compared to $(3.1) million in Q4 2024, an improvement of 131.9% year-over-year Free cash flow of $1.2 million, compared to $(1.6) million in Q4 2024, an improvement of 173.4% year-over-yearFull-Year 2025 and Second Half 2025 HighlightsRevenue of $34.8 million, an increase of 22.1% year-over-year, with H2 revenue...

The U.S. Food and Drug Administration (“FDA”) accepted Celcuity’s New Drug Application (“NDA”) and granted Priority Review with a Prescription Drug User Fee Act (“PDUFA”) goal date of July 17, 2026, for gedatolisib in HR+/HER2-/PIK3CA wild-type (“WT”) advanced breast cancer (“ABC”) Results from PIK3CA WT cohort of Phase 3 VIKTORIA-1 study of gedatolisib regimens in HR+/HER2- ABC published in Journal of Clinical Oncology Topline results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 study are expected to be released in the second quarter of 2026 Management to host webcast and conference call today, March 25, 2026, at 4:30 p.m. EDTMINNEAPOLIS, March 25, 2026 (GLOBE NEWSWIRE) — Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial...